I’ve been leading a project recently, commissioned by our CCG, around the management of Type II Diabetic patients in the primary care setting. The work package concerned a clinical audit focussing on GLP-1 agonist prescribing; with particular reference to value for money vs clinical efficacy.

I’ve found it to be a relatively tricky field to evaluate not least because of the fact you have to factor in the patient in conjunction with NICE guidelines. I now better understand the interplay between each. NICE guidelines offer a template on which to work. However, as a healthcare professional we need to bear in mind patient related factors such as formulation preference, comorbidities and lifestyle.

One reference that I found particularly useful to summarise the current treatment model is as follows: https://www.bmj.com/content/bmj/suppl/2016/04/06/bmj.i1575.DC1/diabetes-t2a-v19-web.pdf

I thought I would share so that others can benefit from the information contained within.